Silexan

Developed for: post-traumatic stress disorder
Investigated by: Deakin University · Ramsay Clinic Albert Road · University of Melbourne

today NCT06412757 · Ph 3

202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT06412757	Aug 2024 → May 2027 expected	post-traumatic stress disorder	Deakin University	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Silexan	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06412757 ↗
Route	Oral	“take two over-encapsulated capsules, each containing 80 mg Silexan, daily orally in the morning” NCT06412757 ↗